Announcements
At TrialStat, we offer comprehensive medical coding services specifically tailored for clinical trials. Our advanced technology ensures fast and accurate coding of verbatim terms from both our Electronic Data Capture (EDC) system and external sources. With our innovative coding platform, we streamline the coding process, providing efficient and reliable solutions for your clinical research needs.…
Read MoreExcerpt from the Press Release: WALTHAM, Mass., June 22, 2023 (GLOBE NEWSWIRE) — Invivyd, Inc. (Nasdaq: IVVD), a clinical-stage biopharmaceutical company on a mission to protect the vulnerable from serious viral infectious diseases, today announced positive initial data from its ongoing Phase 1 healthy volunteer clinical trial of its lead investigational monoclonal antibody (mAb) candidate,…
Read MorePhase 2 Data at EULAR Suggested Profervia® Treatment Might Influence Systemic Sclerosis (SSc) Disease Severity Excerpt from the Press Release: BOSTON, June 21, 2023 /PRNewswire/ — Aisa Pharma, Inc. a private, clinical-stage biopharmaceutical company today announced initiation of Part 2 of the RECONNOITER Phase 2 study, evaluating Profervia®, a once-daily novel, oral calcium-channel antagonist (CCB) in patients with SSc…
Read MoreAdaptive clinical trial designed to accelerate registration pathways for pancreatic cancer therapies and expected to reduce cost of a Phase 3 study for pelareorep by ~50% compared to a traditional trial If successful, new clinical study expected to support approval of pelareorep in combination with a checkpoint inhibitor, gemcitabine, and nab-paclitaxel in first-line metastatic pancreatic…
Read More– NHP studies demonstrate EPI-321’s favorable safety and pharmacokinetic profile – – IND and CTA applications planned for 2023 – Excerpt from the Press Release: SOUTH SAN FRANCISCO, Calif., June 16, 2023 (GLOBE NEWSWIRE) — Epic Bio, a biotechnology company developing therapies to modulate gene expression using compact, non-cutting dCas proteins, today presented new non-human…
Read MoreExcerpt from the Press Release: LEXINGTON, Mass., June 15, 2023 /PRNewswire/ — Pulmatrix, Inc. (NASDAQ: PULM), a clinical-stage biopharmaceutical company developing innovative inhaled therapies to address serious pulmonary and central nervous system disease using its patented iSPERSE™ technology, today announced it will present data at the American Headache Society 65th Annual Meeting, being held from June…
Read MoreExcerpt from the Press Release: SOUTH SAN FRANCISCO, Calif., June 15, 2023 (GLOBE NEWSWIRE) — Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) products for cancer, today at the International Conference on Malignant Lymphoma (ICML) in Lugano, Switzerland presented updated data from the Phase 1…
Read MoreExcerpt from the Press Release: SOUTH SAN FRANCISCO, Calif.–(BUSINESS WIRE)–Verge Genomics, a clinical-stage biotechnology company transforming drug discovery using artificial intelligence and human data, today announced the completion of the Phase 1 clinical trial of VRG50635 in healthy adult volunteers. VRG50635 was dosed up to the maximum single and repeated doses planned, demonstrating a favorable…
Read MoreKAN-101 represents the first agent to modulate the IL-2 biomarker associated with symptomatic responses to gluten exposure in celiac patients KAN-101 advancing in a Phase 1b/2 clinical trial in celiac disease and immune tolerance Excerpt from the Press Release: CAMBRIDGE, Mass. & LAUSANNE, Switzerland–(BUSINESS WIRE)–Anokion SA, a clinical-stage biotechnology company focused on treating autoimmune disease…
Read MoreExcerpt from the Press Release: EMERYVILLE, Calif., June 07, 2023 (GLOBE NEWSWIRE) — 4D Molecular Therapeutics (Nasdaq: FDMT, 4DMT, or the Company), a clinical-stage biotherapeutics company harnessing the power of directed evolution for targeted genetic medicines, today announced positive interim clinical data from the 4D-710 Phase 1/2 AEROW clinical trial for the treatment of cystic…
Read More